Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.

Wei-Chieh LeeTing-Wei LiaoTien-Yu ChenHsiu-Yu FangYen-Nan FangHuang-Chung ChenYu-Sheng LinShang-Hung ChangMien-Cheng Chen

Published in: Cardiovascular drugs and therapy (2023)

Sacubitril/valsartan had a lower all-cause mortality compared to ACEI/ARB in symptomatic HFrEF patients with CKD. Further prospective randomized studies are warranted to confirm our findings.

Keyphrases

chronic kidney disease
heart failure
end stage renal disease
ejection fraction
double blind
open label
placebo controlled
phase iii
left ventricular
phase ii
case control
clinical trial
acute heart failure
cardiac resynchronization therapy
randomized controlled trial